I am a nanomaterial immunoengineer studying how drug delivery vehicles shape innate immune responses to the next generation of nucleic acid therapies. I'm launching the Biomaterial Research for Immunomodulation, Drug delivery, and Genetic Engineering (BRIDGE) lab in January 2026 in the Department of Bioengineering at the University of Oregon, where we'll apply polymer chemistry, pharmaceutical science, and materials science fundamentals in the pursuit of immunology questions and answers. By bridging barriers to delivery, we will translate safer, more potent vaccines with cost-effective global health impact and invent in situ immunotherapies for cancer and regenerative medicine. I've dedicated my life to improving medicine, uplifting young scientists, and learning forever--please reach out if you or someone you know is interested in joining the team as a PhD student, postdoc, or research staff!
During my postdoc in the labs of Prof. Dame Molly Stevens and Prof. Robin Shattock at the University of Oxford and Imperial College London, I worked on 3D-printed protein vaccine delivery systems, saRNA vaccine manufacturing scale-up, and adjuvanted antiviral and antibacterial RNA vaccines. Prior to moving to the UK in 2020, I received my PhD in Bioengineering at the University of Washington under the guidance of Prof. Suzie Pun and Prof. Drew Sellers in collaboration with Prof. Patrick Stayton, where I used controlled polymerization techniques to engineer nucleic acid and cancer vaccine delivery systems. My earliest research experiences were at the University of Maryland, Johns Hopkins University, and the US Food and Drug Administration in my home state.